Some DEGs like FREM2, ANXA2 and GPC4 revealed common enrichment in LE/IT tumor regions across GBM patient samples compared to the overall downregulation of the OPC/OL marker MBP, the neural marker NTRK2, and the ECM glycoprotein EDIL3 (Fig. 8C). This evidence concerns the gene ANXA2 and glioblastoma.